Gynecologic Cancers

Latest News

The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.
FDA Accepts Relacorilant NDA for Platinum-Resistant Ovarian Cancer

September 10th 2025

The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.

Patients with recurrent or metastatic cervical cancer in Hong Kong are now eligible to receive treatment with tisotumab vedotin.
Tisotumab Vedotin Earns Hong Kong Approval in Recurrent Cervical Cancer

September 4th 2025

Health Canada Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer
Health Canada Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

September 4th 2025

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes
Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

July 25th 2025

Avutometinib/Defactinib Displays Safety, Efficacy in Ovarian Cancer Subtype
Avutometinib/Defactinib Displays Safety, Efficacy in Ovarian Cancer Subtype

July 14th 2025

Latest CME Events & Activities